Reccomendation of Polish Respiratory Society for palliative care in chronic lung diseases;Zalecenia Polskiego Towarzystwa Chorób płuc dotyczące opieki paliatywnej w przewlekłych chorobach płuc

Pneumonologia i Alergologia Polska

Volumn 80, Issue 1, 2012, Pages 41-64

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855170636     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (204)

1. Buist A.S., McBurnie M.A., Vollmer W.M. I wsp. BOLD Colla-borative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
2. European Lung White Book. The first comprehensive survey on respiratory health in Europe. Loddenkemper R. (red.). ERS 2003.
3. Bednarek M., Maciejewski J., Wozniak M. I wsp. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax 2008; 63: 402-440.
4. Nizankowska-Mogilnicka E., Mejza F., Buist A. S. I wsp. Preva-lence of COPD and Tobacco smoking in Malopolska region - results from the BOLD study in Poland. Pol. Arch. Med. Wewn. 2007; 117: 402-410.
5. ECAP. Samoliński B. (red.). Epidemiologia chorób alergicznych w Polsce. www.ecap.pl
6. Didkowska J., Wojciechowska U., Tarnowski W. I wsp. Nowot-wory złośliwe w Polsce w 2006 roku. Centrum Onkologii-Instytut im. M. Skłodowskiej-Curie, Warszawa 2008.
7. Korzeniewska-Koseła M. (red.). Gruźlica i choroby układu odd-echowego w Polsce w 2009 roku. Instytut Gruźlicy i Chorób Płuc, Warszawa 2010.
8. Muers M.F., Round C.E. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax 1993; 48: 339-343.
9. Sawicki G.S., Seller D.E., Robinson W.M. Self-reported physi-cal and psychological symptom burden in adults with cystic fibrosis. J. Pain Sympt. Manage. 2008; 35: 37-380.
10. Walke L.M., Byers A.L., Tinetti M.E. I wsp. Range and severity of symptoms over time among older adults with chronic obstructive pulmonary disease and heart failure. Arch. Intern. Med. 2007; 164: 2321-2324.
11. Burgel P.R., Nesme-Meyer P., Chanez P. I wsp. Cough and spu-tum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975-982.
12. Golbeck L., Besier T., Hinz A. I wsp. Prevalence of anxious and depressive symptoms in German patients with cystic fibrosis. Chest 2010; DOI 10.1378/chest.09-2940.
13. Boulet L.P., Phillips R., O'Byrne P., Becker A. Evaluation of asthma control by physicians and patients: comparison with current guidelines. Can. Respir. J. 2002; 9: 417-423.
14. King P.T., Holdworth S.R., Freezer N.J. I wsp. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir. Med. 2006; 100: 2183-2189.
15. Ryu Y.J., Chun E.M., Lee J.H., Chang J.H. Prevalence of depres-sion and anxiety in outpatients with chronic airway lung disease. Korean J. Intern. Med. 2010; 25: 51-57.
16. Sepúlveda C., Marlin A., Yoshida T., Ullrich A. Palliative Care: The World Health Organization's Global Perspective. J. Pain Symptom. Manage. 2002; 24: 91-96.
17. http://www.who.int/cancer/palliative/definition/en/
18. Griffin J.P., Koch K.A., Nelson J.E. I wsp. Palliative care con-struction, quality-of-life measurements, and bereavement for end-of-life care in patients with lung cancer. Chest 2007; 132 (supl.): 404-422.
19. Buczkowski K., Krajnik M. (red.). Opieka paliatywna. Wy-dawnictwo Lekarskie PZWL, Warszawa 2009.
20. Murray S.A., Kendall M., Boyd K., Sheikh A. Illness trajectories and palliative care. BMJ 2005; 330: 1007-1011.
21. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman-Sanchez P. I wsp. Severe acute exacerbations and mortality in patients with COPD. Thorax 2005; 60: 925-931.
22. Eriksen N., Vestbo J. Management and survival of patients ad-mitted with an exacerbation of COPD: comparison of two Danish patient cohorts. Clin. Respir. J. 2010; 4: 208-214.
23. Budweiser S., Hitzl A.P., Jorres R.A. I wsp. Health-related qual-ity of life and long-term prognosis in chronic hypercapnic respiratory failure: a prospective survival analysis. Respir. Res. 2007; 8: 92.
24. Budweiser S., Jorres R. A., Riedl T. I wsp. Predictors of survival in COPD patients with chronic hypercapnic respiratory failure receiving noninvasive home ventilation. Chest 2007; 131: 1650-1658.
25. www.ginasthma.com
26. Gaga M., Papageorgiou N., Yiourgioti G. I wsp. ENFUMOSA Study Group. Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin. Exp. Allergy 2005; 35: 954-959.
27. Selman M., Carrillo G., Estrada A. I wsp. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PloS ONE 2007; 2: e482.
28. Mackay L.S., Anderson R.L., Parry G. I wsp. Pulmonary fibro-sis: rate of disease progression as a trigger for referral for lung transplantation. Thorax 2007; 62: 1069-1073.
29. Collard H.R., Moore B.B., Flaherty K.R. I wsp. Acute exacerba-tions of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2007; 176: 636-643.
30. Kim D.S., Park J.H., Park B.K. I wsp. Acute exacerbation of idiopathic pulmonary fibrosis; frequency and clinical features. Eur. Respir. J. 2006; 27: 143-150.
31. Park I.N., Jegal Y., Kim D.S. I wsp. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur. Respir. J. 2009; 33: 68-76.
32. Latsi P.I., du Bois R.M., Nicholson A.G. I wsp. Fibrotic idio-pathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med. 2003; 168: 531-537.
33. Ryu J.H., Myers J.L., Capizzi S.A. I wsp. Desquamative intersti-tial pneumonia and respiratory bronchiolitis interstitial lung disease. Chest 2005; 127: 178-184.
34. Grutters J.C., Wells A.U., Wuyts W. Evaluation and treatment of interstitial lung involvement in connective tissue diseases; a clinical update. Eur. Respir. Mon. 2006; 34: 27-49.
35. Cordier J.-F. Organizing pneumonia: cryptogenic and disease associated. Semin. Respir. Crit. Care Med. 2003; 24: 595-603.
36. Silva C.I., Muller N.L., Lynch D.A. I wsp. Chronic hypersensi-tivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thinsection CT. Radiology 2008; 246: 288-297.
37. Katzenstein A.-L.A., Mukhopadhyay S., Myers J.L. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Human Pathol. 2008; 39: 1275-1294.
38. Olson A.L., Huie T.J., Groshong S.D. I wsp. Acute exacerba-tions of fibrotic hypersensitivity pneumonitis: a case series. Chest 2008; 134: 844-850.
39. Iannuzzi M.C., Rybicki B.A., Teirstein A.S. Sarcoidosis. N. Engl. J. Med. 2007; 357: 2153-2165.
40. Walsh T.J., Anaissie E.J., Denning D.W. I wsp. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 2008; 46: 327-360.
41. Vassallo R., Ryu J.H., Schroeder D.R. I wsp. Clinical outcomes of pulmonary Langerhans'cell histiocytosis in adults. N. Engl. J. Med. 2002; 346: 484-490.
42. Ryu J.H., Moss J., Beck G.J. I wsp. The NHLNI lymphangiolei-omyomatosis registry: characteristics of 230 patients at enrollment. Am. J. Respir. Crit. Care Med. 2006; 173: 105-111.
43. Seymour J.F., Presneill J.J. Pulmonary alveolar proteinosis: Progress in the first 44 years. Am. J. Respir. Crit. Care Med. 2002; 166: 215-235.
44. Zamora A.C., Collard H.R., Wolters P.J. I wsp. Neurofibromato-sis-associated lung disease: a case series and literature review. Eur. Respir. J. 2007; 29: 210-214.
45. Mariotta S., Ricci A., Papale M. I wsp. Pulmonary alveolar mi-crolithiasis: review on 576 cases published in the literature. Sarcoidosis Vasc. Diffuse Lung Dis. 2004; 21: 173-181.
46. Chan E.D., Strand M.J., Iseman M.D. Multidrug resistant tuber-culosis (TB) resistant to fluorochinolones and streptomycin but susceptibility to second-line injection therapy has a better prognosis than extensively drug-resistant TB. CID 2009; 48: e50-52.
47. Kliiman K., Altraja A. Predictors of poor outcome in multi-and extensively drug-resistant pulmonary TB. Eur. Respir. J. 2009; 33: 1085-1094.
48. Griffith D.E., Aksamit T., Brown-Elliot B.A. I wsp. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007; 175: 367-416.
49. Dodge J.A., Morison S., Lewis P.A. I wsp. Incidence, popula-tion, and survival of cystic fibrosis in the UK, 1968-95. Arch. Dis. Child 1977; 77: 493-496.
50. McCormick J., Sims E. J., Green M.W. I wsp. Comparative analy-sis of Cystic Fibrosis Registry data from the UK with USA, France and Australia. J. Cyst. Fibr. 2005; 4: 115-122.
51. Dodge J.A., Lewis P.A., Stanton M. I wsp. Cystic fibrosis mor-tality and survival in the UK: 1947-2003. Eur. Respir. J. 2007; 29: 523-526.
52. Conlan A.A., Hurwitz S.S., Krige L. I wsp. Massive hemoptysis. Review of 123 cases. J. Thorac. Cardiovasc. Surg. 1983; 85: 120-124.
53. Didkowska J., Wojciechowska U., Tarnowski W. I wsp. Nowot-wory złośliwe w Polsce w 2006 roku. Centrum Onkologii-Insytut im. M. Skłodowskiej-Curie, Warszawa 2008.
54. Naruke T., Goya T., Tsuchiya R. I wsp. Prognosis and survival in resected lung carcinoma based on the international staging system. J. Thorac. Cardiovasc. Surg. 1998; 96: 440-447.
55. Halbert R. J., Natoli J. L., Gano A. I wsp. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 2006; 28: 523-532.
56. Batura-Gabryel H. Zmiany ogólnoustrojowe u chorych na prze-wlekła{ogonek} obturacyjna{ogonek} chorobe{ogonek} płuc. Pneumonol. Alergol. Pol. 2009; 77: 180-185.
57. Dotter J., Hami F., Bryan T., Quigley C. Symptoms in 400 pa-tients referred to palliative care service: prevalence and pattern. Palliat. Med. 2003; 17: 310-314.
58. Dudgeon D.J., Kristjanson L., Sloan J. A. I wsp. Dyspnea in cancer patients: prevalence and associated factors. J. Pain Symptom. Manage 2001; 21: 95-102.
59. www.goldcopd.com
60. Agarwal R., Jindal S.K. Acute ecacerbation of idiopatic pulmo-nary fibrosis: a systematic review. Eur. J. Intern. Med. 2008; 19: 227-235.
61. Walters J.A., Gibson P.G., Wood-Baker R. I wsp. Systemic corti-costeroids for acute exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2009; CD001288.
62. Navigante A.H., Cerchietti L.C., Castro M.A. I wsp. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J. Pain Symptom. Manage 2006; 31: 38-47.
63. Simon S.T., Higginson I.J., Booth S. I wsp. Benzodiazepines for the relief of breathlessness in advanced malignant and nonmalignant diseases in adults. Cochrane Database Syst. Rev. 2010: CD007354.
64. Jennings A.L., Davies A.N., Higgins J.P.T. I wsp. a systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-944.
65. Currow D.C., Mc Donald C., Oaten S. I wsp. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J. Pain Symptom. Manage. 2011; 42: 388-399.
66. Rocker G., Horton R., Currow D.C. I wsp. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax 2009; 64: 910-915.
67. Larkin P.J., Sykes N.P., Centeno C. I wsp. The management of constipation in palliative care: clinical practice recommendations. Palliat. Med. 2008; 22: 796-807.
68. Bruera E., Sala R., Spruyt O. I wsp. Nebulized versus subcuta-neous morphine for patients with cancer dyspnea: a preliminary study. J. Pain Symptom. Manage. 2005; 29: 613-618.
69. Galbraith S., Fagan P., Perkins P. I wsp. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J. Pain Symptom. Manage. 2010; 39; 831-838.
70. Gift A.G., Moore T., Soeken K. Relaxation to reduce dyspnea and anxiety in COPD patients. Nurs. Res. 1988; 17: 408-413.
71. Solà I., Thompson E., Subirana M. I wsp. Non-invasive interventions for improving well-being and quality of life in patients with lung cancer. Cochrane Database Syst. Rev. 2004: CD004282.
72. Birring S.S., Prudon B., Carr A.J. I wsp. Development of a symp-tom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58: 339-343.
73. Kelsall A., Decalmer S., Webster D. I wsp. How to quantify coughing: correlations with quality of life. Eur. Respir. J. 2008; 32: 175-179.
74. Freestone C., Eccles R. Assessment of the antitussive efficacy of codeine in cough associated with common cold. J. Pharmacy Pharmacol. 1997; 49: 1045-1049.
75. Parvez L., Vaidya M., Sakhardande A. I wsp. Evaluation of antitussive agents in man. Pulm. Pharmacol. 1996: 9: 299-308.
76. Smith J., Owen E., Earis J., Woodcock A. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2006; 117: 831-835.
77. Ramsay J., Wright K., Thompson R. I wsp. Assessment of anti-tussive efficacy of dextromethorphan in smoking related cough: objective vs. subjective measures. Br. J. Clin. Pharmacol. 2008; 65: 737-741.
78. Daviskas E., Anderson S.D., Eberl S., Young I.H. Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction. Respir. Med. 2010; 104: 1645-1653.
79. Wills P., Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst. Rev 2006: CD002996.
80. Kvale P.A. Palliative care in lung cancer. Chest 2007; 132: 368-403.
81. Hyde L., Hyde C.I. Clinical manifestations of lung cancer. Chest 1974; 65: 299-306.
82. Remiszewski P., Broniek A., Roszkowski K., Pawlicka L. Rozlane krwawienia pe{ogonek}cherzykowe w przebiegu ziarniniakowa- tości Wegenera. Pneumonol. Alergol. Pol. 1996; 64: 71-77.
83. Szopiński J., Kamiński Z., Bestry I., Bogdan J. Płucne przetoki te{ogonek}tniczo-żylne. Pneumonol. Alergol. Pol. 1994; 62: 634-639.
84. Plaza V., Serra-Batlles J., Falco M. I wsp. Have the causes of hemoptysis changed? An analysis of 213 patients undergoing fiber bronchoscopic exploration. Arch. Bronconeumol. 1995; 31: 323-327.
85. Jougon J., Ballester M., Delcambre F. I wsp. Massive hemopty-sis: what place for medical and surgical treatment. Eur. J. Cardiothorac. Surg. 2001; 22: 345-351.
86. Swanson K.L., Johnson C.M., Prakash B.S. I wsp. Bronchial artery embolization. Experience with 54 patients. Chest 2002; 121: 789-795.
87. Antonelli M., Midulla F., Tancredi G. I wsp. Bronchial artery embolization for the management of nonmassive hemoptysis in cystic fibrosis. Chest 2002; 121: 796-801.
88. Senkus-Konefka E., Dziadziuszko R. Bednaruk-Młyński E. I wsp. A prospective, randomized study to compare two palliative radiotherapy schedules for non-small cell lung cancer. Br. J. Cancer 2005; 92: 1038-1045.
89. Medical Research Council Lung Cancer Working Party. A Med-ical Research Council randomised trial of palliative radiothera-py with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br. J. Cancer 1992; 65: 934-941.
90. Kelly J.F., Delclos M.E., Morice R.C. I wsp. High-dose-rate en-dobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48: 697-702.
91. Seto A.H., Dunlap D.S. Tranexanic acid in oncology. Ann. Pha-macother. 1996; 30: 868-870.
92. Gagnon B., Mancini I., Pereira J. I wsp. Palliative management of bleeding events in advanced cancer patients. J. Palliat. Care 1998; 14: 50-54.
93. Dean A., Tuffin P. Fibrinolytic inhibitors for cancer associated bleeding problems. J. Pain Symptom. Manage. 1997; 13: 20-24.
94. Dobrogowski J., Mayzner-Zawadzka E., Drobnik L. I wsp. Uśmi-erzanie bólu pooperacyjnego - zalecenia 2008. Ból 2008; 9.
95. Groeben H. Epidural anesthesia and pulmonary function. J. Anesth. 2006; 20: 290-299.
96. Gruber E., Tschernko E. Anaesthesia and postoperative analge-sia in older patients with chronic obstructive pulmonary disease - special considerations. Drugs Aging 2003; 20: 347-360.
97. Licker M., Schweizer A., Ellenberger C. I wsp. Perioperative medical management of patients with COPD. Int. J. COPD 2007; 2: 493-515.
98. Pergolizzi J., Boger R.H., Budd K. I wsp. Opioidy i poste{ogonek}po-wanie w cie{ogonek}żkim bólu przewlekłym u osób starszych: konsensus mie{ogonek}dzynarodowego panelu ekspertów, ze szczególnym uwzgle{ogonek}dnieniem sześciu najcze{ogonek}ściej stosowanych w praktyce klinicznej opioidów z III stopnia drabiny analgetycznej wg WHO (buprenorfina, fentanyl, hydromorfon, metadon, morfina, oksykodon). Onkol. Prakt. Klin. 2008; 4 (supl. C).
99. Dworkin R.H., O'Connor A.B., Backonja M. I wsp. Pharmaco-logic management of neuropathic pain: evidence-based recommendations. Pain 200; 132: 237-251.
100. Dobrogowski J., Przeklasa-Muszyńska A., Woroń J., Wordliczek J. Zasady kojarzenia leków terapii bólu. Med. Pal. Prakt. 2007; 1: 6-15.
101. Wordliczek J., Dobrogowski J. (red.). Leczenie bólu. Wydawnict-wo Lekarskie PZWL, Warszawa 2011.
102. Zajaczkowska R., Krajnik M., Woroń J. I wsp. Leczenie bóluu pacjentów z terminalna{ogonek} niewydolnościa{ogonek} narza{ogonek}dowa{ogonek}. Terapia 2011; 10: 19-30.
103. Dobrogowski J., Krajnik M., Jassem J., Wordliczek J. Stanowis-ko dotycza{ogonek}ce poste{ogonek}powania przeciwbólowego u chorych na no-wotwory. Onkol. Prakt. Klin. 2009; 2: 55-68.
104. National Comprehensive Cancer Network (NCCN) clinical prac-tice guidelines in oncology: cancer and treatment related anemia, version 1.2009. Search under "Guidelines for supportive care".
105. Mendoza T.R., Wang X.S., Cleeland C.S. I wsp. The rapid as-sessment of fatigue in cancer patients. Cancer 1999; 85: 1186-1196.
106. Vogelzang N.J., Breitbart W., Cella D. I wsp. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin. Hematol. 1997; 34 (3 supl. 2): 4-12.
107. Curt G.A., Breitbart W., Cella D. I wsp. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5: 353-360.
108. de Vries J., Rothkrantz-Kos S., Dieijen-Visser M.P. I wsp. The relationship between fatigue and clinical parameters in pulmo-nary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2004; 21: 127-136.
109. Roscoe J.A., Morrow G.R., Hickok J.T. I wsp. Temporal interre-lationships among fatigue, cicardian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support. Care Cancer 2002; 10: 329-336.
110. Tchekmedyian N.S., Kallich J., McDermott A. I wsp. The rela-tionship between psychological distress and cancer-related fa-tigue. Cancer 2003; 98: 198-203.
111. Jacobsen P.B., Donovan K.A., Weitzner M.A. Distinguishing fa-tigue and depression in patients with cancer. Semin. Clin. Neu-ropsychiatry 2003; 8: 229-240.
112. Visser M.R., Smets E.M. Fatigue, depression and quality of life in cancer patients: how are they related? Support. Care Cancer 1998; 6: 101-108.
113. Bruera E., Driver L., Barnes E.A. I wsp. Patient-controlled me-thylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J. Clin. Oncol. 2003; 21: 4439-4443.
114. Minton O., Richardson A., Sharpe M. I wsp. A systematic re-view and meta-analysis of the pharmacological treatment of cancer-related fatigue. J. Natl. Cancer Inst. 2008; 100: 1155-1166.
115. Spatihis A., Dhillan R., Bowden D. I wsp. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat. Med. 2009; 23: 325-331.
116. Jean-Pierre P., Morrow G. R., Roscoe J.A. I wsp. A phase 3 randomized, placebo controlled, double-blind, clinical trial of the effect of modafinil on cancer related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 2010; 116: 3513-3520.
117. Morrow G.R., Hickok J.T., Roscoe J.A. I wsp. Differential effect of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester cancer Center Community Clinical Oncology Program. J. Clin. Oncol. 2003; 21: 4635-4641.
118. Stockler M.R., O'Connell R., Nowak A.K. I wsp. Effect of sertra-line on symptoms and survival in patients with advanced cancer, but without major depression: a placebo controlled, double-blind randomised trial. Lancet Oncol. 2007; 8: 603-612.
119. Bruera E., Roca E., Cedaro L. I wsp. Action of oral methylpred-nisolone in terminal cancer patients: a prospective randomised double-blind study. Cancer Treat. Rep. 1985; 69: 751-754.
120. Bruera E., Elosta B., Valero V. I wsp. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J. Clin. Oncol. 2007; 25: 3475-3481.
121. Barsevick A.M., Dudley W., Beck S. I wsp. A randomized clini-cal trial of energy conservation for patients with cancer-related fatigue. Cancer 2004; 100: 1302-1310.
122. Pietras T., Witusik A., Panek M. I wsp. Le{ogonek}k i depresja u chorych na choroby obturacyjne płuc. Pol. Merk. Lek. 2009; 26: 631-635.
123. Janssen D.J., Spruit M.A., Leue C. I wsp. Symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation. Chron. Respir. Dis. 2010; 7: 147-157.
124. Mulrow C.D., Williams J.W. Jr, Gerety M.B. I wsp. Case-finding instruments for depression in primary care setting. Ann. Intern. Med. 1995; 122: 913-921.
125. Bailey P. The dyspnea-anxiety-dyspnea cycle: COPD patients' stories of breathlessness. Qual. Health Res. 2004; 14: 760-778.
126. Thomas S., Bausewein C., Higginson I., Booth S. Breathlessness in cancer patients implications, management, and challenges. Eur. J. Oncol. Nurs. 2011; DOI 10.1016/j.ejon.2010.11.013.
127. von Leupoldt A., Mertz C., Kegat S. I wsp. The impact of emo-tions on the sensory and affective dimension of perceived dyspnea. Pathophysiology 2006; 43: 382-386.
128. Nq T., Niti M., Tan W. I wsp. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch. Intern. Med. 2007; 167: 60-67.
129. Yohannes A., Balwin R., Connoly M. Depression and anxiety in elderly patients with chronic obstructive pulmonary disease. Age Ageing 2006; 35: 457-459.
130. de Walden-Gałuszko K. Zaburzeniasnu. W: Psychoonkologia w praktyce klinicznej. Wydawnictwo Lekarskie PZWL, Warszawa 2011; 38-42.
131. Argyropoulou P., Patakas D., Koukou A. I wsp. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 1993; 6: 216-220.
132. Singh N.P., Despars J.A., Stansbury D.W. I wsp. Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety. Chest 1993; 103: 800-804.
133. Voogd J., Wempe J., Koeter G. I wsp. Depressive symptoms as predictors of mortality in patients with COPD. Chest 2009; 135: 619-625.
134. Strom K., Boman G., Pehrsson K. I wsp. Effect of protriptiline, 10 mg daily, on chronic hypoxemia in chronic obstructive pulmonary disease. Eur. Respir. J. 1995; 8: 425-429.
135. Lacasse Y., Beaudoin L., Rousseau L., Maltais F. Randomized trial of paroxetine in end-stage COPD. Monaldi Arch. Chest Dis. 2004; 61: 140-147.
136. Eiser N., Harte R., Karvounis S. I wsp. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD 2005; 2: 233-241.
137. Kunik M., Rondy K., Veazey C. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005; 127: 1205-1211.
138. Glennon C., Seskevich J. Relaxation techniques to easy dyspnea: a tool for oncology nurses. Clin. J. Oncol. Nurs. 2008; 12: 359-371.
139. Effing T., Monninghof E.M., van der Valk P.D. I wsp. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Review. 2007: CD 002990.
140. Pierzchała W., Barczyk G., Górecka D. I wsp. Zalecenia Pol-skiego Towarzystwa Chorób Płuc rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc (POChP). Pneumonol. Alergol. Pol. 2010; 78: 318-347.
141. Pływaczewski R., Śliwiński P., Nowiński A. I wsp. Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy. Chest 2000; 117: 679-683.
142. Skwarski K. Nocna hipoksemia i zaburzenia rytmu serca u chorych z przewlekła{ogonek} obturacyjna{ogonek} choroba{ogonek} płuc. Pol. Arch. Med. Wewn. 1989; 81: 283-294.
143. Śliwiński P., łagosz M., Górecka D., Zieliński J. The adequacy of oxygenation in COPD patients undergoing long-term oxygen therapy assessed by pulse oximetry at home. Eur. Respir. J. 1994; 7: 274-278.
144. Goldstein R.S., Ramcharan C., Bowes G. I wsp. Effect of supplemental oxygen on gas exchange in patients with severe obstructive lung disease. N. Engl. J. Med. 1984; 310: 425-429.
145. O'Donnell D.E., Sain D.J., Webb K.A. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am. J. Respir. Crit. Care Med. 1997; 155: 530-535.
146. Somfay A., Porszasz J., Lee S. M., Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patents. Eur. Respir. J. 2001; 18: 77-84.
147. O'Donnell D.E., D'Arsigny C., Webb K.A. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med 2001; 163: 892-898.
148. Nonoyama M.L., Brooks D., Lacasse Y. I wsp. Oxygen therapy during exercise training in chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007: CD005372.
149. Bruera E., de Stoutz N., Velasco-Leiva A. I wsp. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342: 13-14.
150. Booth S., Kelly M.J., Cox N.P. I wsp. Does oxygen help dyspnea in patients with cancer? Am. J. Respir. Crit. Care Med. 1996; 153: 1515-1518.
151. Schettino G., Altobelli N., Kacmarek R.M. Noninvasive positive pressure ventilation reverses acute respiratory failure in selected "do-not-intubate" patients. Crit. Care Med. 2005; 33: 1976-1982.
152. Abernethy A.P., McDonald C.F., Frith P.A. I wsp. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnea: a double-blind, randomized controlled trial. Lancet 2010; 376: 784-793.
153. Liss H.P., Grant B.J. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1988; 137: 1285-1288.
154. Chu C.-M., Chan V.L., Wong I.W.Y. I wsp. Noninvasive ventilation in patients with acute hypercapnic exacerbation of chronic obstructive pulmonary disease who refused endotracheal intubation. Crit. Care Med. 2004; 32: 372-377.
155. Bott J., Carrol M. P, Conway J. H. I wsp. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993; 341: 1555-1557.
156. Cuomo A., Conti G., Delmastro M. I wsp. Noninvasive mechanical ventilation as a palliative treatment of acute respiratory failure in patients with end-stage solid cancer. Palliat. Med. 2004; 18: 602-610.
157. Chronic obstructive pulmonary disease: non-invasive ventilation with bi-phasic positive airways pressure in the management of patients with acute type 2 respiratory failure. Royal College of Physicians, British Thoracic Society, Intensive Care Society.
158. Concise Guidance to Good Practice series, No 11. London: RCP, 2008.
159. Celli B.R., MacNee W. ATS/ERS Task Force. Standards for the Diagnosis and Treatment of Patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004; 23: 932-946.
160. Nava S., Sturani C., Hart S. I wsp. End-of-life decision-making in respiratory intermediate care units: a European survey. Eur. Respir. J. 2007; 30: 156-164.
161. Krajewski R. w imieniu Roboczej Grupy ds. problemów Etycznych Końca Życia. Komentarz do definicji. Med. Paliat. Prakt. 2008; 2: 78.
162. Nici L., Donner C., Wouters E. I wsp. American Thoracic Society//European Respiratory Society Statement on Pulmonary Rehabilitation. Am. J. Respir. Crit. Care Med. 2006; 173: 1390-1413.
163. Gigliotti F., Coli C., Bianchi R. I wsp. Arm exercise and hyperinflation in patients with COPD. Effect of arm training. Chest 2005; 128: 1225-1232.
164. Mador M. J., Deniz O., Aggarval A. I wsp. Effect of respiratory muscle endurance training in patients with COPD undergoing pulmonary rehabilitation. Chest 2005; 128: 1216-1224.
165. Lotters F., van Tol B., Kwakkel G. I wsp. Effects of controlled inspiratory muscle training in patients with COPD: a metaanalysis. Eur. Respir. J. 2002; 20: 570-576.
166. Troosters T., Casaburi R., Gosselink R. I wsp. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 9-38.
167. Foglio K., Bianchi L., Bruletti G. I wsp. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur. Respir. J. 1999; 3: 125-132.
168. Foglio K., Bianchi L., Ambrosino N. Is it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airways obstruction? A 2-year controlled study. Chest 2001; 119: 1696-1704.
169. Kozu R., Senjyu H., Jenkins S.C. I wsp. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration 2010; 79: 454-460.
170. Clini E., Foglio K., Bianchi L. I wsp. In-hospital short-term training program for patients with chronic airway obstruction. Chest 2001; 120: 1500-1505.
171. Plankeel J.F., McMullen G., MacIntyre N.R. Exercise outcomes after pulmonary rehabilitation depend on the initial mechanisms of exercise limitation among non-oxygen-dependent COPD patients. Chest 2005; 127: 110-116.
172. Cote C.G., Celli B.R. Pulmonary rehabilitation and the BODE index in COPD. Eur. Respir. J. 2005; 20: 630-636.
173. Bołoz W. Rezygnacja z uporczywej terapii jako realizacja praw człowieka umieraja{ogonek}cego. Med. Paliat. Prakt. 2008; 2: 79-85.
174. Bołoz W. Krajnik M., Adamczyk A. I wsp. Definicja uporczywej terapii. Konsensus polskiej grupy roboczej do spraw problemów etycznych końca życia. Med. Paliat. Prakt. 2008; 2: 77-78.
175. Kodeks etyki lekarskiej, art. 32. Naczelna Izba Lekarska. Warszawa 2010.
176. Curtis J.R. Palliative and end-of-life care for patients with severe COPD. Eur. Respir. J. 2008; 32: 796-809.
177. Skilbeck J., Mott L., Page H. Palliative care in chronic obstructive pulmonary airways disease: a needs assessment. Palliat. Med. 1998; 12: 245-254.
178. Gore J.M., Brophy C.J., Greenstone M.A. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000; 55: 1000-1006.
179. Binnebesel J., Janowicz A., Krakowiak P., Paczkowska A. (red.). Pozamedyczne aspekty opieki paliatywno-hospicyjnej. Via Medica, Gdańsk 2010.
180. Curtis J.R., Engelberg R.A., Nielsen E.L. I wsp. Patient-physician communication about end-of-life for patients with severe COPD. Eur. Respir. J. 2004; 24: 200-205.
181. Jones I., Kirby A., Ormiston P. The needs of patients dying of chronic obstructive pulmonary disease in the community. Fam. Pract. 2004; 21: 310-313.
182. Habraken J.M., van der Wal W.M., ter Riet G. I wsp. Health-related quality of life and functional status in end-stage COPD: a longitudinal study. Eur. Respir. J. 2011; 37: 280-288.
183. Shaw R.E., Cohen F., Doyle B., Palesky J. The impact of denial and repressive style on information gain and rehabilitation outcomes in myocardial infarction patients. Psychosom. Med. 1985; 47: 262-273.
184. Janiszewska J. Dobra komunikacja warunkiem wsparcia psy-chicznego chorych umieraja{ogonek}cych. Nowa Medycyna - Opieka Paliatywna 2004; 2: 12-15.
185. Gerstman S. Rozmowa i wywiad w psychologii. Wydawnictwo Nukowe PWN, Warszawa 1976.
186. Krakowiak P. Zda{ogonek}żyć z prawda{ogonek}. O sztuce komunikacji w hospicjum. Via Medica, Gdańsk 2006.
187. Back A.L., Curtis J.R. Communicating bad news. West. J. Med. 2002; 176: 177-180.
188. Detering K.M., Hancock A.D., Reade M.C., Silvester W. The impact of advanced care planning on end of life care in elderly patients: randomized controlled trial. BMJ 2010; 340: c1345.
189. de Walden-Gałuszko K. Przekazywanie złych informacji. W: U kresu. Opieka psychopaliatywna, czyli jak pomóc choremu, rodzinie i personelowi medycznemu środkami psychologicznymi. Wydawnictwo Medyczne Makmed, Gdańsk 2000; 88-92.
190. www.who.int/entity/mediacentre/factsheete/fs172/en
191. Jassem E., Kozielski J., Górecka D. I wsp. Integrated care for patients with advanced chronic obstructive pulmonary disease: a new approach to organization. Pol. Arch. Med. Wewn. 2010; 120: 423-428.
192. Coventry P.A., Grande G.E., Richards D.A., Todd C.J. Prediction of appropriate timing of palliative care for older adults with non-malignant life-threatening disease, a systematic review. Age Ageing 2005; 34: 218-227
193. Dean M.M. End-of-life care for COPD patients. Prim. Care Resp. J. 2008; 17: 46-50.
194. Downey L., Curtis J.R., Lafferty W.E. I wsp. The quality of dying and death questionnaire (QoDD): emipirical domains and theoretical perspectives. J. Pain Symptom. Manage 2010; 39: 9-22.
195. Zarzadzenie Prezesa Narodowego Funduszu Zdrowia (nr 63//2009/DSOZ z dnia 2 listopada 2009 r. w sprawie określenia warunków zawierania i realizacji umów w rodzaju opieka paliatywna i hospicyjna.
196. Radbruch L., Payne S., Zarzad EAPC. Raport dotycza{ogonek}cy standardów i norm dla opieki hospicyjnej i paliatywnej w Europie: cze{ogonek}ść 1. Zalecenia Europejskiego Towarzystwa opieki paliatywnej. Med. Paliat. Prakt. 2010; 4: 41-53 (www.mpp.viamedica.pl).
197. Krakowiak P., Modlińska A., Binnebesel J. (red.). Podre{ogonek}cznik koordynatora wolontariatu hospicyjnego. Via Medica, Gdańsk 2008.
198. Radbruch L., Payne S., Zarzad EAPC. Raport dotycza{ogonek}cy standardów i norm dla opieki hospicyjnej i paliatywnej w Europie: cze{ogonek}ść 2. Zalecenia Europejskiego Towarzystwa opieki paliatywnej. Med. Paliat. Prakt. 2010; 4: 54-65 (www.mpp.viamedica.pl).
199. Jagielski D., Graczyk M., Jagielska A., Krajnik M. Is there room for a palliative care support team in an emergency hospital ward? Analysis of the palliative care support team activity at the University Hospital, Bydgoszcz, in 2002-2006. Adv. Palliat. Med. 2008; 7: 55-60.
200. Modlinska A. Formy wolontariatu hospicyjnego. Wolontariat medyczny. W: Krakowiak P., Modlinska A., Binnebesel J. (red.). Podre{ogonek}cznik koordynatora wolontariatu hospicyjnego. Via Medica, Gdańsk 2008: 57-59.
201. Patel I. Integrated respiratory care: what forms may it take and what are the benefits to patients. Breathe 2010; 6: 253-259.
202. Marciniuk D., Goodridge D., Hernandez P. I wsp. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: A Canadian Thoracic Society clinical practice guideline. Can. Respir. J. 2011; 18: 69-78.
203. Booth S., Bausewein C., Higginson I. I wsp. Pharmacological treatment of refractory breathlessness. Expert. Rev. Respir. Med. 2009; 3: 21-36.
204. Kapella M.C., Larson J.L., Patel M.K. I wsp. Subjective fatigue, influencing variables, and consequences in chronic obstructive pulmonary disease. Nurs. Res. 2006; 55: 10-17.